CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
ActiTOX develops an innovative in vitro testing platform to evaluate the toxicity of nanoparticles and drugs. By utilizing advanced technologies like biomimetic scaffolds and microfluidics, it aims to enhance the relevance of pre-clinical studies and improve drug development processes.
Nanoparticles and new drugs are undergoing complex toxicity evaluation prior to their use in products for customers.However, the traditional pre-clinical testing protocols are delivering significant disadvantages both from ethical (animaltesting) and functional (high attrition rate in clinical testing) point of view.
ActiTOX reacts to this problem by the developmentof a novel, pre-clinical, high content, in vitro testing platform focused on the evaluation of nanoparticles/drugs via ADME(absorpti…
FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EV
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Czechia, Praha
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Austria, Wien
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Hungary, Gyor
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Germany, Berlin
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
